Positive Quality Intervention: Olanzapine (Zyprexa®) In Chemotherapy Induced Nausea and Vomiting

Description: This PQI will examine the use of olanzapine (Zyprexa®) in the treatment of chemotherapy induced nausea and vomiting (CINV).

Background: Olanzapine is an FDA approved atypical antipsychotic that blocks multiple neuronal receptors involved in nausea/vomiting pathways.1 Olanzapine has been studied for breakthrough2 CINV as well as prophylaxis of highly and moderately emetogenic regimens.3-5 Additionally, olanzapine has been studied in replacement of NK1 receptor antagonists (ex. aprepitant) as well as in addition to standard triplet prophylaxis regimens which include NK1 receptor antagonists.4-7 The results of these trials suggest olanzapine is at least as effective as aprepitant and combination olanzapine with aprepitant has led to promising reports of CINV control. Based on the results from these various studies, national guidelines (National Comprehensive Cancer Network guideline on Antiemesis) recommend olanzapine 5-10 mg PO daily as an option within prophylaxis regimens for highly emetogenic chemotherapy (HEC) and often moderately emetogenic chemotherapy (MEC) regimens. Clinically, lower doses of 5 mg and 2.5 mg have been used in patients where sedation may be a concern. Nausea and vomiting remain a common and difficult to manage side effect of chemotherapy despite prophylaxis. These symptoms can often lead to a decreased quality of life, dehydration, and malnutrition. Historically, patients have been prescribed dexamethasone along with a 5HT3 antagonist (ex. ondansetron) to prevent nausea and vomiting. For patients receiving HEC/MEC, a NK1 receptor antagonist, such as fosaprepitant, is added to the antiemesis regimen. Despite the use of these dual and triple agent preventative strategies as recommended by national guidelines, nausea and vomiting remains a significant complication of chemotherapy.

PQI Process: Upon receipt of an order for a HEC or MEC chemotherapy regimen

- Screen for appropriate antiemesis medications
  - Dexamethasone
  - 5HT3 Antagonist
  - NK1 Receptor Antagonist
  - +/- Olanzapine
- If olanzapine if not initially included in the orders, consider recommending the addition of olanzapine 5-10 mg by mouth daily days 1 through 4 of chemotherapy
- If the patient is elderly or over-sedated, consider using a lower dose upon initiation8
- Use caution when prescribing olanzapine with metoclopramide or haloperidol, as this combination may lead to a higher risk of extrapyramidal symptoms

Patient-Centered Activities:

- Patient Compliance
  - Encourage patients to take this medication each day, as prescribed
  - Compliance is particularly important for any patients receiving HEC/MEC regimens in the outpatient setting
- Patient Education
  - Explain CINV and the different medications that are being prescribed to help prevent nausea and vomiting
  - Outline the reason patients take olanzapine on days 1 through 4 only*
  - Olanzapine may be administered without regard to meals
  - Review common side effects with the patient9

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 11.13.23

* life, dehydration, and malnutrition.

Historically, patients have been prescribed dexamethasone along with a 5HT3 antagonist (ex. ondansetron) to prevent nausea and vomiting. For patients receiving HEC/MEC, a NK1 receptor antagonist, such as fosaprepitant, is added to the antiemesis regimen. Despite the use of these dual and triple agent preventative strategies as recommended by national guidelines, nausea and vomiting remains a significant complication of chemotherapy.

PQI Process: Upon receipt of an order for a HEC or MEC chemotherapy regimen

- Screen for appropriate antiemesis medications
  - Dexamethasone
  - 5HT3 Antagonist
  - NK1 Receptor Antagonist
  - +/- Olanzapine
- If olanzapine if not initially included in the orders, consider recommending the addition of olanzapine 5-10 mg by mouth daily days 1 through 4 of chemotherapy
- If the patient is elderly or over-sedated, consider using a lower dose upon initiation8
- Use caution when prescribing olanzapine with metoclopramide or haloperidol, as this combination may lead to a higher risk of extrapyramidal symptoms

Patient-Centered Activities:

- Patient Compliance
  - Encourage patients to take this medication each day, as prescribed
  - Compliance is particularly important for any patients receiving HEC/MEC regimens in the outpatient setting
- Patient Education
  - Explain CINV and the different medications that are being prescribed to help prevent nausea and vomiting
  - Outline the reason patients take olanzapine on days 1 through 4 only*
  - Olanzapine may be administered without regard to meals
  - Review common side effects with the patient9

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 11.13.23

*
- Drowsiness
- Headache
- Disturbed sleep
- Increased appetite
- Constipation
- Extrapyramidal reaction
- Orthostatic hypotension

Drowsiness will potentially diminish over time

*Some multiple day HEC regimens may call for more than 4 days of olanzapine*

References: